KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection.

Josh Claypool, Gustav Lindved, Pernille Neve Myers, Tonya Ward, Henrik Bjørn Nielsen, Ken F Blount

Gut Microbes 17(1) 2520412

PMID40552763
PMCIDPMC12931727
DOI10.1080/19490976.2025.2520412
发表日期2025-06-24
入排依据:未发现恶性肿瘤人群证据。
已检查 10 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;另有 5 张未列出。
摘要

摘要

Live microbiota therapies have shown promise in many gastrointestinal diseases, including in the prevention of recurrent Clostridioides difficile infections (rCDI); however, frameworks for their pharmacokinetic and pharmacodynamic analysis are not fully established. Fecal microbiota, live-jslm (RBL) is the first microbiota-based product approved by the US Food and Drug Administration for the prevention of rCDI and was superior to placebo in the PUNCH™ CD3 phase 3 clinical trial (NCT03244644). In this analysis, deep shotgun metagenomic sequencing was used to assess changes in gut microbiome compositions of participants and engraftment of bacterial clonal populations (i.e. strains) from RBL to recipients. Among RBL responders, gut microbiota shifted toward compositions that resembled healthy donors as early as 1 week after RBL administration; the resulting microbiota compositions included clonal populations that engrafted from RBL to recipients. Engraftment was higher in RBL responders compared with non-responders, and many clonally engrafted populations persisted for ≥ 6 months. Bacteroidia species were among the most effectively engrafted species from RBL. This study utilizes data from a large clinical trial to establish a method with high specificity for exploring clonal engraftment from microbiota-based treatments to facilitate future pharmacokinetic and pharmacodynamic analyses.Clinicaltrials Registration: NCT03244644.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(10,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. NMDS of Bray-Curtis distance calculated on species-level taxonomy of stool samples for baseline and post-RBL administration time points. The black outlined circles represent the centroid of each group or time point. NMDS, non-metric multidimensional scaling; RBL, fecal microbiota, live-jslm.
非 KM Figure
Figure 2Figure 2. Group mean relative abundances (π) with 95% standard error for the 7 most abundant bacterial classes in participants administered RBL and placebo, based on Dirichlet multinomial. RBL, fecal microbiota, live-jslm.
非 KM Figure
Figure 3Figure 3. a) Species richness and b) number of newly appearing species following RBL and placebo administration. Median (thick horizontal lines) and interquartile ranges (boxes) are shown. Significance assessed via Wilcoxon rank-sum test. ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.0001. RBL, fecal microbiota, live-jslm.
非 KM Figure
Figure 4Figure 4. Number of engrafting species at each time point in participants administered RBL or placebo. Median (thick horizontal lines) and interquartile ranges (boxes) are shown. RBL, fecal microbiota, live-jslm.
非 KM Figure
Figure 5Figure 5. Engraftment among subgroups by a) outcome, b) sex, c) antibiotics used, d) age, and e) number of prior CDI episodes for participants administered RBL ( n = 95). Median (thick horizontal lines) and interquartile ranges (boxes) are shown. CDI, Clostridioides difficile infection; F, female; M, male; RBL, fecal microbiota, live-jslm.
非 KM Figure
Figure 6Figure 6. The fraction of species in post-administration RBL participant samples for which clonal engraftment from RBL was observed. Median (thick horizontal lines) and interquartile ranges (boxes) are shown. * p < 0.0001; RBL, fecal microbiota, live-jslm.
非 KM Figure
Figure 7Figure 7. Engraftment effectiveness for all species within bacterial classes with ≥ 1 engraftment event detected. The median engraftment effectiveness per class is denoted by a heavy vertical line, with interquartile ranges denoted by boxes.
非 KM Figure
Figure 8Figure 8. Per species engraftment effectiveness and bile acid gene composition in participants administered RBL. Blue dots represent the engraftment effectiveness for that species across RBL doses and participants, dashed lines represents the median engraftment effectiveness for species within that class of bacteria, gray dots signify the presence of the denoted gene within the reference genome for that species, and red gradient represents the number of RBL doses in which each species is found. Only species present in ≥ 20% of doses were analyzed. RBL, fecal microbiota, live-jslm.
非 KM Figure
Figure 9Figure 9. Persistence of per-species engraftment effectiveness over time for species engrafting in ≥ 5 participants. The number of participants with engrafting species is designated as n next to the species name with a maximum of n = 33. The blue gradient represents the proportion with engraftment detected for each species at each time point.
非 KM Figure